MD Anderson and Allogene Therapeutics Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy
October 16, 2020
October 16, 2020
HOUSTON, Texas, Oct. 16 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Oct. 15:
The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene's broad portfolio of hematologic and solid tumors.
"MD Anderson's expertise in innovative . . .
The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene's broad portfolio of hematologic and solid tumors.
"MD Anderson's expertise in innovative . . .